Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avatrombopag - Dova Pharmaceuticals

Drug Profile

Avatrombopag - Dova Pharmaceuticals

Alternative Names: AKR-501; AKR-501 monomaleate; Avatrombopag maleate; DOPTELET; E-5501; YM-477

Latest Information Update: 19 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer Dova Pharmaceuticals
  • Class Antithrombotics; Piperazines; Piperidines; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombocytopenia
  • Registered Idiopathic thrombocytopenic purpura

Most Recent Events

  • 27 Jun 2019 Dova Pharmaceuticals expands the marketing agreement with Salix Pharmaceuticals to co-promote Avatrombopag in USA for Thrombocytopenia
  • 27 Jun 2019 Registered for Idiopathic thrombocytopenic purpura (Treatment-experienced) in USA (PO)
  • 27 Jun 2019 Dova Pharmaceuticals anticipates the commercial launch of Avatrombopag for Idiopathic thrombocytopenic purpura in USA, in mid-July 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top